Cytometry Part B-Clinical Cytometry

Papers
(The TQCC of Cytometry Part B-Clinical Cytometry is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Flow cytometric analysis of myelodysplasia: Pre‐analytical and technical issues—Recommendations from the European LeukemiaNet24
Best practices for the development, analytical validation and clinical implementation of flow cytometric methods for chimeric antigen receptor T cell analyses23
A flow cytometric assay for HLA‐DR expression on monocytes validated as a biomarker for enrollment in sepsis clinical trials23
Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS‐Flow 21
An easy and reliable whole blood freezing method for flow cytometry immuno‐phenotyping and functional analyses19
Acute promyelocytic leukemia: Immunophenotype and differential diagnosis by flow cytometry17
Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues17
Multicenter prospective evaluation of diagnostic potential of flow cytometric aberrancies in myelodysplastic syndromes by theELN iMDSflow working group16
ELN iMDS flow working group validation of the monocyte assay for chronic myelomonocytic leukemia diagnosis by flow cytometry15
Comparison of five diagnostic flow cytometry scores in patients with myelodysplastic syndromes: Diagnostic power and prognostic impact15
Normal or reactive minor cell populations in bone marrow and peripheral blood mimic minimal residual leukemia by flow cytometry15
ESCCA/ISCCA protocol for the analysis of cerebrospinal fluid by multiparametric flow‐cytometry in hematological malignancies15
Radar plots facilitate differential diagnosis of acute promyelocytic leukemia and NPM1+ acute myeloid leukemia by flow cytometry14
B‐lineage antigens that are useful to substitute CD19 for minimal residual disease monitoring in B cell precursor acute lymphoblastic leukemia after CD19 targeting13
Exploring dyserythropoiesis in patients with myelodysplastic syndrome by imaging flow cytometry and machine‐learning assisted morphometrics13
Evaluation of multiple myeloma measurable residual disease by high sensitivity flow cytometry: An international harmonized approach for data analysis12
Flow cytometric method transfer: Recommendations for best practice12
Increased TOX expression concurrent with PD‐1, Tim‐3, and CD244 expression in T cells from patients with acute myeloid leukemia12
Chimerism evaluation in measurable residual disease‐suspected cells isolated by flow cell sorting as a reliable tool for measurable residual disease verification in acute leukemia patients after allog12
New cytometry tools for immune monitoring during cancer immunotherapy11
Exploring blast composition in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms: CD45RA and CD371 improve diagnostic value of flow cytometry through ass10
Relevance of polyclonal plasma cells and post‐therapy immunomodulation in measurable residual disease assessment in multiple myeloma9
Routine flow cytometry approach for the evaluation of solid tumor neoplasms and immune cells in minimally invasive samples9
Peripheral innate and adaptive immune cells during COVID‐19: Functional neutrophils, pro‐inflammatory monocytes, and half‐dead lymphocytes9
Illuminating the immunopathology of SARS‐CoV‐29
Flow cytometric assessment for minimal/measurable residual disease in B lymphoblastic leukemia/lymphoma in the era of immunotherapy9
Characteristic CD45RA/CD45RO maturation pattern by flow cytometry associated with the CD45 C77G polymorphism8
PD‐1 improves accurate detection of Sezary cells by flow cytometry in peripheral blood in mycosis fungoides/Sezary syndrome8
Comprehensive immunophenotypic study of acute myeloid leukemia with KMT2A (MLL) rearrangement in adults: A single‐institution experience8
Machine learning optimized multiparameter radar plots for B‐cell acute lymphoblastic leukemia minimal residual disease analysis8
The flow cytometry myeloid progenitor count: A reproducible parameter for diagnosis and prognosis of myelodysplastic syndromes7
Highly sensitive single tube B‐lymphoblastic leukemia/lymphoma minimal/measurable residual disease test robust to surface antigen directed therapy7
A comparison and review of the flow cytometric findings in classic Hodgkin lymphoma, nodular lymphocyte predominant Hodgkin lymphoma, T cell/histiocyte rich large B cell lymphoma, and primary mediasti7
Best practices for optimization and validation of flow cytometry‐based receptor occupancy assays7
Validation of inducible basophil biomarkers: Time, temperature and transportation7
Flow cytometry immunophenotypic features of pure erythroid leukemia and the distinction from reactive erythroid precursors7
Development and validation of a high‐parameter mass cytometry workflow to decipher immunomodulatory changes in celiac disease7
Refractory neutrophils and monocytes in patients with inflammatory bowel disease after repeated bouts of prolonged exercise7
Flow cytometric immunophenotyping of plasma cells across the spectrum of plasma cell proliferative disorders: A fresh insight with pattern‐based recognition6
A rare biclonal Hairy Cell Leukemia disclosed by an integrated diagnostic approach: A case report6
Validation of a new multiparametric protocol to assess viability, acrosome integrity and mitochondrial activity in cooled and frozen thawed boar spermatozoa6
Human leukocyte antigen‐B27 typing by flow cytometry: Comparison of three CE‐IVD methods6
Flow cytometry‐based analysis of tumor‐leukocyte ratios in peritoneal fluid from patients with advanced gastric cancer6
Detection of CAR‐T19 cells in peripheral blood and cerebrospinal fluid: An assay applicable to routine diagnostic laboratories6
Bicentric evaluation of stabilizing sampling tubes for assessment of monocyte HLA‐DR expression in clinical samples6
A series of case studies illustrating the role of flow cytometry in the diagnostic work‐up of myelodysplastic syndromes6
Correlation between a 10‐color flow cytometric measurable residual disease (MRD) analysis and molecular MRD in adult B‐acute lymphoblastic leukemia6
Use of flow cytometry and cytology to differentiate breast implant‐associated anaplastic large cell lymphoma from reactive seromas in Brazilian patients5
The impact of Down syndrome‐specific non‐malignant hematopoietic regeneration in the bone marrow on the detection of leukemic measurable residual disease5
Resolving 31 colors on a standard 3‐laser full spectrum flow cytometer for immune monitoring of human blood samples5
Mature B‐ and plasma‐cell flow cytometric analysis: A review of the impact of targeted therapy5
Unsupervised cluster analysis and subset characterization of abnormal erythropoiesis using the bioinformatic Flow‐Self Organizing Maps algorithm5
Erroneous expression of NKG2D on granulocytes detected by phycoerythrin‐conjugated clone 149810 antibody5
Validation of a 12‐color flow cytometry assay for acute myeloid leukemia minimal/measurable residual disease detection5
Immunophenotypic characteristics of ZNF384 rearrangement compared with BCR‐ABL1, KMT2A rearrangement, and other adult B‐cell precursor 5
Summary of validation considerations with real‐life examples using both qualitative and semiquantitative flow cytometry assays5
Analysis of human chromosomes by imaging flow cytometry5
Flow cytometry to detect bone marrow involvement by follicular lymphoma5
Circulating CD22+/CD19−/CD24− progenitors and CD22+/CD19+/CD24− mature B cells: Diagnostic pitfalls for minimal residual disease detec4
Combined use of different antibody clones improves the efficiency of human leukocyte antigen B27 detection by flow cytometry4
Flow cytometric analysis of CD34+CD38− cells; cell frequency and immunophenotype based on CD45RA expression pattern4
Time point‐dependent concordance and prognostic significance of flow cytometry and real time quantitative PCR for measurable/minimal residual disease detection in acute myeloid leukemia wit4
CD69flow cytometry to complement interferon‐γrelease assay for active tuberculosis4
Diagnostic utility of flow cytometry based coated‐platelets assay as a biomarker to predict thrombotic or hemorrhagic phenotype in acute stroke4
Malignant plasmacytes in bone marrow detected by flow cytometry as a predictor for the risk stratification system of multiple myeloma4
CLL/SLL specifically binding to the APC fluorochrome: A previously undescribed phenomenon4
0.032054901123047